Singapore - Pfizer, a global leader in biopharmaceuticals, is proud to announce that its Bio Processing division in the Asia-Pacific region (APAC) has surpassed the remarkable milestone of generating over 1 billion USD in revenues. This exceptional achievement is a testament to the dedication and expertise of the entire Bio Processing APAC team, and Vice President Srikumar Ramakrishnan commends their outstanding contribution.
Under the visionary leadership of Vice President Srikumar Ramakrishnan, Pfizer's Bio Processing APAC division has played a pivotal role in advancing bioprocessing technologies and bringing life-saving therapies to patients across the APAC region. The division's relentless pursuit of scientific excellence, coupled with its focus on operational efficiency, has resulted in exceptional financial success and solidified Pfizer's position as a leading biopharmaceutical company.
"I am immensely proud of the Bio Processing APAC team for achieving this significant milestone," said Vice President Srikumar Ramakrishnan. "Their unwavering commitment to innovation, quality, and patient-centricity has been instrumental in driving our success in the region. This achievement is a testament to their hard work, dedication, and relentless pursuit of excellence."
The Bio Processing APAC division of Pfizer is renowned for its state-of-the-art facilities, cutting-edge technologies, and robust manufacturing processes. By leveraging these capabilities, the team has successfully developed and produced a diverse portfolio of biologics, including vaccines, therapeutic proteins, and gene therapies, to address the healthcare needs of patients in the APAC region.
As Pfizer continues to expand its presence in APAC, Vice President Srikumar Ramakrishnan affirms the company's commitment to investing in research and development, fostering collaborations with local partners, and driving sustainable healthcare solutions. By working closely with stakeholders, the Bio Processing APAC team will continue to make significant contributions to the growth of the biopharmaceutical industry and the well-being of patients in the region.
About Pfizer:
Pfizer is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines and vaccines that improve the health and well-being of people around the world. With a diverse portfolio of products, Pfizer's research and development efforts encompass both small molecules and biologics across a range of therapeutic areas. The company's mission is to be a leader in driving science-based healthcare solutions that address the unmet needs of patients.
For media inquiries, please contact:
Sarah Johnson
Media Relations Manager
